Thomas Boone, MD
Family Medicine · Chewelah, WANPI 1346325750
Payments from drug & device makers
Across 292 payments — averaging $13.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$660
- Pfizer$626
- Amgen$617
- AstraZeneca$463
- Boehringer Ingelheim$331
- AbbVie$166
- plus $939 from 21 others
What the payments were for
- Food & beverage$3,74498%
- Education$582%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 51 | $660 |
| Pfizer | 81 | $626 |
| Amgen | 40 | $617 |
| AstraZeneca | 35 | $463 |
| Boehringer Ingelheim | 12 | $331 |
| AbbVie(2 entities) | 10 | $166 |
| Supernus Pharmaceuticals, Inc. | 11 | $134 |
| Otsuka America Pharmaceutical, Inc. | 6 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $93 |
| Lilly USA, LLC | 6 | $89 |
| Phathom Pharmaceuticals, Inc. | 7 | $89 |
| GSK | 5 | $66 |
| Teva Pharmaceuticals USA, Inc. | 3 | $52 |
| Bayer | 3 | $47 |
| Astellas Pharma US Inc | 2 | $39 |
| Corcept Therapeutics | 2 | $35 |
| Dexcom, Inc. | 1 | $27 |
| Johnson & Johnson | 1 | $24 |
| Sanofi Pasteur Inc. | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Medtronic | 1 | $19 |
| Lundbeck LLC | 1 | $16 |
| Novartis | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| Shire North American Group Inc | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
How this compares
$3,802 in reported general payments places this provider in the 90th percentile of 2,275 family medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 181 | $119,872 |
| JardianceEmpagliflozin | 99 | $95,332 |
| EliquisApixaban | 118 | $81,745 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $51,300 |
| OzempicSemaglutide | 27 | $38,592 |
| XareltoRivaroxaban | 46 | $33,407 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 45 | $31,318 |
| RybelsusSemaglutide | 19 | $24,501 |
| RexultiBrexpiprazole | 11 | $18,772 |
| Repatha SureclickEvolocumab | 25 | $13,414 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 20 | $12,947 |
| MyrbetriqMirabegron | 12 | $12,543 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 29 | $12,172 |
| TrintellixVortioxetine Hydrobromide | 16 | $12,014 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 588 | $11,359 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $463 | $151,189226 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $331 | $108,278119 claims |
| PfizerEliquis, Premarin | $626 | $83,983129 claims |
| Novo NordiskOzempic, Rybelsus | $660 | $63,09446 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $66 | $63,04084 claims |
| Johnson & JohnsonXarelto | $24 | $33,40746 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $95 | $18,77211 claims |
| Astellas Pharma US IncMyrbetriq | $39 | $12,54312 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $93 | $12,01416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,275 family medicine providers in Washington.
Other family medicine in Chewelah
- Anton GraschWenatchee$5.3M
- Gaylon KippBellevue$4.8M
- Steven KasterWenatchee$4M
- Angela EakinSpokane$3M
- Jonathan StabenCheney$2.5M
- Emily ZaragozaSeattle$1.9M
- Brad FrandsenPort Orchard$1.7M
- Kevin HatfieldSeattle$527K
- Steven SmithAuburn$438K
- John RobinsonEdmonds$425K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.